Posts by: Joana Carvalho

Joana Carvalho

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.

October 25, 2019

Blincyto Increases Survival of ALL Children, Adolescents After First Relapse, Phase 3 Trials Show

News

Blincyto (blinatumomab) increases overall survival and disease-free survival in children and adolescents with B-cell acute lymphoblastic leukemia (ALL) who already had their first relapse, data from Phase 3 trials show. ... Read more

October 23, 2019November 7, 2019

CHMP Favors Keytruda Regimens to Treat Recurrent Head and Neck Cancers

News

The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has recommended that two regimens of Keytruda (pembrolizumab) be approved in Europe for first-line ... Read more

October 2, 2019

Tecentriq Prolongs Survival of Patients with Advanced Lung Cancer Beyond Chemo, Phase 3 Trial Shows

News

Tecentriq (atezolizumab) prolongs the lives of patients with advanced non-squamous and squamous non-small cell lung cancer (NSCLC) when administered as a first-line therapy, compared to chemotherapy, according to the interim ... Read more

October 1, 2019

Opdivo Boosts Long-Term Survival of Advanced Lung Cancer Patients, Phase 3 Trials Show

News

Opdivo (nivolumab) continues to increase the long-term overall survival of patients with advanced non-small cell lung cancer (NSCLC) compared to the chemotherapy Taxotere (docetaxel), according to pooled data from two ... Read more

September 24, 2019

Ilixadencel-Sutent Combo Shows Efficacy in Advanced Kidney Cancer, Phase 2 Trial Reports

News

A combination of ilixadencel plus Sutent (sunitinib) is showing promising efficacy in patients with kidney cancer that has spread to other organs, according to topline data from a Phase 2 ... Read more

September 18, 2019

First-line Imfinzi-Chemo Therapy Extends Survival of Patients with Aggressive Lung Cancer, Phase 3 Trial Shows

News

Adding the immune checkpoint inhibitor Imfinzi (durvalumab) to standard chemotherapy care significantly extends the survival of patients with untreated extensive-stage small cell lung cancer (ES-SCLC), an aggressive form of lung ... Read more

September 11, 2019

FDA Grants Orphan Drug Status to BioXcel’s BXCL701 as Potential AML Treatment

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to BXCL701, one of BioXcel Therapeutics’ lead immunotherapies for the treatment of acute myeloid leukemia (AML). Orphan drug ... Read more

September 10, 2019

Health Canada and European Commission OK Tecentriq-Chemo Combo for Aggressive Lung Cancer

News

Health Canada and the European Commission have approved Tecentriq (atezolizumab) in combination with chemotherapy (carboplatin plus etoposide) as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), an ... Read more

August 16, 2019September 4, 2019

ADXS-NEO Provoked Strong Immune Response in Advanced Cancer Patient, Early Trial Data Show

News

ADXS-NEO, an investigational cancer immunotherapy, induced an immune response against 90% of all cancer targets in a patient with metastatic microsatellite stable colorectal cancer (MSS-CRC), data from an ongoing Phase ... Read more

August 7, 2019

Phase 1b Trial of Cabometyx-Tecentriq Combo in Solid Cancers Adding More Patients, Tumor Types

News

Two initial patient groups have been expanded and four others added to a Phase 1b trial assessing the combination therapy Cabometyx (cabozantinib) and Tecentriq (atezolizumab) in people with locally advanced or metastatic solid ... Read more